After Roche’s exit, Blueprint passes Gavreto on to Rigel

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug

Lilly bags label extension for RET drug Retevmo in US

Eli Lilly's cancer drug Retevmo has just had its eligible patient population increased in the US.

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

Eli Lilly's RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England and Wales, within the Cancer D

Roche, Blueprint's RET cancer drug Gavreto cleared in EU

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, after getting approval for Gavreto from the European Commission.

Lilly keeps ahead of Blueprint with swift FDA review for sel...

Relief for Lilly as drug from $8bn Loxo deal clears pivotal ...